Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
NCT02650817
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
RAD1901
Sponsor
Stemline Therapeutics, Inc.